首页 | 本学科首页   官方微博 | 高级检索  
     

骨髓增生异常综合征患者血红素加氧酶表达水平及其临床意义
引用本文:解杰,李丽珍,黄涛,王鲁群,李颢,李湘新,王玲玲,李芳邻. 骨髓增生异常综合征患者血红素加氧酶表达水平及其临床意义[J]. 新医学, 2014, 0(2): 99-103
作者姓名:解杰  李丽珍  黄涛  王鲁群  李颢  李湘新  王玲玲  李芳邻
作者单位:[1]山东大学齐鲁医院血液科, 济南250012 [2]山东大学医学院诊断学研究所, 济南250012
基金项目:山东省科技攻关基金(2006GG3202047),山东省优秀中青年科研奖励基金(BS2009YY049)
摘    要:
目的:观察初诊低危骨髓增生异常综合征(MDS)患者血红素加氧酶-1(HO-1)表达水平的变化及其基础水平与患者预后的关系,探讨HO-1在该病中可能的作用机制和临床应用前景。方法收集60例初诊低危 MDS 患者以及20例缺铁性贫血(IDA)患者的骨髓单个核细胞(BMMNCs),予不同浓度(0、5、10、20μM)的HO-1诱导剂Hemin体外孵育,用蛋白免疫印迹法检测HO-1蛋白表达水平和MAPK信号通路中c-Jun氨基末端激酶(JNK)磷酸化表达水平的变化,并随访分析HO-1的基础表达水平与患者无进展生存期(PFS)的关系。结果①低危 MDS 患者BMMNCs中HO-1蛋白基础表达水平与IDA患者比较差异无统计学意义(P>0.05);随着Hemin干预浓度的增加,HO-1蛋白表达量逐渐升高,JNK信号分子磷酸化表达水平亦逐渐升高,呈浓度依赖性(均为P<0.05);② HO-1高表达的患者PFS长于低表达患者组(中位数41.6个月 vs.32.0个月,P=0.047)。COX回归分析显示HO-1表达水平是判断低危MDS患者预后的独立因素(P=0.006)。结论在低危MDS患者中,HO-1高表达者预后较好,HO-1可能通过JNK信号分子途径影响MDS的疾病过程。上调HO-1有可能成为改善疾病预后的新的治疗靶点。

关 键 词:血红素加氧酶-1  骨髓增生异常综合征  c-Jun氨基末端激酶  预后  Heme  oxygenase-1

Expression of heme oxygenase and its clinical significance in myelodysplastic syndromes patients
XIE Jie,LI Li-zhen,HUANG Tao,WANG Lu-qun,LI Hao,LI Xiang-xin,WANG Ling-ling,LI Fang-lin. Expression of heme oxygenase and its clinical significance in myelodysplastic syndromes patients[J]. New Chinese Medicine, 2014, 0(2): 99-103
Authors:XIE Jie  LI Li-zhen  HUANG Tao  WANG Lu-qun  LI Hao  LI Xiang-xin  WANG Ling-ling  LI Fang-lin
Affiliation:(Depart- merit of Hematology, Qilu Hospital of Shandong University, Jinan 250012, China)
Abstract:
Objective To investigate the relationship between the expression level of heme oxygen-ase-1 (HO-1 )and the prognosis of lower-risk myelodysplastic syndromes (MDS)patients,and to explore the possible mechanism and clinical significance that HO-1 may involve.Methods Sixty newly diagnosed low-risk MDS patients and twenty iron deficiency anemia (IDA)patients were enrolled in this study.Isolated bone marrow mononuclear cells (BMMNCs)were cultured in the presence or absence of Hemin (inducer of HO-1 ) at different final concentrations of 5,1 0,20 μMfor 48 h.Western blotting were performed to detect HO-1 ex-pression and the activity of c-Jun N-terminal kinases (JNK)in BMMNCs.The relationship between HO-1 ex-pression levels and duration of progression-free survival (PFS)were further analyzed.Results ①No signifi-cant difference in HO-1 expression was observed between the low-risk MDS patients and the IDA patients (P〉0.05).After treated with different concentrations of Hemin,HO-1 and phosphorylated JNK (p-JNK)expres-sion levels of BMMNCs increased gradually in a dose-dependent manner (P〈0.05).② The median duration of PFS of patients with higher expression level of HO-1 was significantly longer than those with lower expression level of HO-1 (41 .6 months vs.32.0 months,P=0.047).COX regression showed that HO-1 was an inde-pendent prognostic factor (P=0.006).Conclusion High expression of HO-1 in low-risk MDS is associated with good prognosis,JNK signaling pathway might be involved in the effect of HO-1 on the progress of MDS, Up-regulation of HO-1 may be a new way to improve the prognosis of MDS.
Keywords:Myelodysplastic syndromes  C-Jun N-terminal kinases  Prognosis
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号